SAN JUAN, Puerto Rico,
July 27, 2017 /PRNewswire/
-- Abarca Health, a pharmacy benefit management (PBM) and
technology company that serves more than two million lives across
the nation, has signed a value-based reimbursement contract with
Biogen Inc. (NASDAQ: BIIB) for select products in Biogen's leading
multiple sclerosis (MS) portfolio. This first-of-its-kind agreement
between the companies offers an innovative approach to connecting
outcomes with the effective net cost of the products. The agreement
places accountability on Biogen to deliver safety, efficacy, and
value for the patients who receive these life-impacting therapies
and for the payers who finance them.
"We are excited to partner with Biogen in
implementing this innovative, data-driven, and outcomes-based
pricing program for MS drug therapies. We believe this
program is a significant milestone in our efforts to collaborate
with pharmaceutical manufacturers to find a better way to guide
patients and payers down the path to value, especially in high
impact disease categories," stated Javier
Gonzalez, Chief Operating Officer of Abarca Health.
This contract builds on Abarca Health's ongoing work with Biogen
to find better ways to collaborate in the treatment of patients
afflicted with complex, high-cost conditions.
"We believe that contracting approaches like this will help
expand access for patients. We are excited to work with an
innovative partner like Abarca Health and lead the way for MS
care." said Jean-Paul Kress,
Executive Vice President and President, International and Head of
Global Therapeutic Operations of Biogen.
Outcomes-based contracting is an important part of the future of
healthcare. By partnering with manufacturers such as Biogen, Abarca
Health is ensuring greater accountability around the investments
made by payers and patients in high cost treatments, which leads to
better access and better outcomes for patients.
About ABARCA HEALTH
As a pharmacy benefit management
and technology company, Abarca Health serves more than 2 million
people across the nation helping its clients manage over
$1 billion in pharmaceutical
spending. The company leverages its people, culture and technology
to develop deep partnerships with health plans, government
programs, self-insuring employer and union groups, among other
payers - partnerships that are both authentic and flexible. By
building trust with and delivering consistently for its customers,
Abarca is able to better work together to create a healthcare
experience that cares for us like family, guides us on the path to
value, and inspires us to live better every day. For more
information, please visit www.abarcahealth.com.
About BIOGEN
Through cutting-edge science and
medicine, Biogen discovers, develops and delivers worldwide
innovative therapies for people living with serious neurological
and neurodegenerative diseases. Founded in 1978, Biogen is a
pioneer in biotechnology, and today the company has the leading
portfolio of medicines to treat multiple sclerosis; has introduced
the first and only approved treatment for spinal muscular atrophy;
and is at the forefront of neurology research for conditions
including Alzheimer's disease, Parkinson's disease and amyotrophic
lateral sclerosis. Biogen also manufactures and commercializes
biosimilar of advanced biologics. For more information, please
visit www.biogen.com.
View original
content:http://www.prnewswire.com/news-releases/abarca-health-and-biogen-announces-innovative-value-based-contract-for-multiple-sclerosis-therapies-300495565.html
SOURCE Abarca Health